Cell Reports Medicine
Scope & Guideline
Empowering researchers with accessible, high-impact findings.
Introduction
Aims and Scopes
- Translational Medicine:
The journal emphasizes studies that translate basic research findings into clinical practice, promoting innovations that can directly benefit patient care. - Multi-Omics Approaches:
Research utilizing integrated multi-omics methodologies (genomics, proteomics, metabolomics) to explore complex biological systems and disease mechanisms is a key focus area. - Cancer Research:
A significant portion of the published works addresses cancer biology, including therapeutic strategies, biomarker discovery, and immunotherapy advancements. - Immunology and Infection:
The journal features studies on immune responses, host-pathogen interactions, and vaccine development, particularly in the context of emerging infectious diseases. - Personalized Medicine:
Research aimed at understanding individual variability in response to treatment and the development of personalized therapeutic strategies is highlighted. - Microbiome Research:
Investigations into the role of microbiota in health and disease, including their interactions with the immune system and implications for therapeutic interventions, are prevalent.
Trending and Emerging
- Artificial Intelligence in Medicine:
The application of AI and machine learning for diagnostics, treatment prediction, and personalized medicine is rapidly gaining traction, as evidenced by an increasing number of publications. - Immunotherapy and Cancer Vaccines:
Research exploring novel immunotherapeutic strategies, including CAR T-cell therapy and vaccine development for cancer treatment, is on the rise. - Gut-Brain Axis and Metabolism:
Studies examining the interactions between the gut microbiome and neurobiology, particularly in relation to metabolic diseases and mental health, are becoming more prominent. - Long COVID and Post-Acute Sequelae:
Research focused on the long-term effects of COVID-19, including immune responses and therapeutic interventions for post-acute sequelae, has emerged as a critical area. - Gene Editing and CRISPR Technologies:
Innovations in gene editing technologies, particularly CRISPR applications for therapeutic purposes, are increasingly featured, reflecting advancements in genetic medicine.
Declining or Waning
- Traditional Pharmacology:
Research focused solely on conventional pharmacological approaches without integrating modern techniques such as genomics or proteomics appears to be less frequently published. - Basic Science without Clinical Relevance:
Papers that do not establish a clear connection between laboratory findings and clinical implications are becoming less common, as the journal prioritizes translational research. - Single-Disciplinary Studies:
There is a noticeable decrease in studies that focus exclusively on one discipline (e.g., pure biology or chemistry) without interdisciplinary approaches, as the journal seeks comprehensive insights.
Similar Journals
Journal of Translational Medicine
Facilitating Collaboration for Medical Breakthroughs.Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Bridging Molecular Biology and Clinical InsightsBIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.
GROWTH FACTORS
Connecting researchers to the forefront of scientific discovery.GROWTH FACTORS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to advancing the field of cell biology, clinical biochemistry, and endocrinology. With an ISSN of 0897-7194 and an E-ISSN of 1029-2292, this journal has served as a vital platform for the dissemination of groundbreaking research since its inception in 1988. Although it operates without an Open Access model, GROWTH FACTORS focuses on providing high-quality, peer-reviewed articles that explore the intricate roles of growth factors in biological processes and their implications in health and disease. Holding a Q4 ranking in Cell Biology and Q3 rankings in Clinical Biochemistry and Endocrinology according to the 2023 category quartiles, the journal is well-regarded in its field and plays a crucial role in informing researchers, professionals, and students alike about the latest findings and innovations in these areas. The journal's commitment to fostering scientific dialogue ensures that it remains a key resource for those looking to enhance their understanding of growth factors and their applications in clinical settings.
IN VIVO
Unveiling the complexities of life sciences for a healthier tomorrow.IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.
Byulleten Sibirskoy Meditsiny
Connecting Innovators in Biomedical SciencesByulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.
CYTOKINE & GROWTH FACTOR REVIEWS
Transforming Research with Comprehensive ReviewsCYTOKINE & GROWTH FACTOR REVIEWS, published by Elsevier Science Ltd, serves as a premier platform for the dissemination of cutting-edge research in the fields of Biochemistry, Genetics and Molecular Biology, Endocrinology, and Immunology. With an impressive impact factor that places it in the Q1 category across multiple disciplines, the journal brings together high-quality reviews that critically evaluate recent advances in cytokine and growth factor biology. This ensures that researchers and professionals have access to valuable insights that enhance current knowledge and stimulate further investigation. Although it is not an open-access journal, its rigorous selection process and high ranking – including Rank #7 in Medicine: Endocrinology, Diabetes and Metabolism – underscore its significance within the scientific community. With its converged years of publication from 1996 to 2024, CYTOKINE & GROWTH FACTOR REVIEWS remains a crucial resource for students, researchers, and professionals alike, informing their work with comprehensive overviews of key topics in the dynamic interplay of growth factors and cytokines.
Journal of Biomedical Research
Elevating Biomedical Research Through Rigorous ScholarshipJournal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.
LIFE SCIENCES
Elevating the discourse in molecular biology and medicine.LIFE SCIENCES, published by PERGAMON-ELSEVIER SCIENCE LTD, is an esteemed international journal that has been advancing the field since its inception in 1962. With an ISSN of 0024-3205 and an E-ISSN of 1879-0631, it serves as a critical forum for researchers, professionals, and students within the realms of biochemistry, genetics, molecular biology, medicine, and pharmacology. Currently ranked in the Q1 category across multiple disciplines, including a remarkable 2nd rank in General Pharmacology, Toxicology, and Pharmaceutics, the journal maintains a prestigious position in academic circles, evidenced by its high impact factor and significant percentile ranks. While LIFE SCIENCES is not an open-access journal, it remains dedicated to publishing high-quality, peer-reviewed research that pushes the boundaries of knowledge and fosters innovation. With converged research interests leading into 2024, LIFE SCIENCES continues to be a pivotal resource for the dissemination of influential findings, making it an indispensable tool for those engaged in the life sciences.
MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.
M S-MEDECINE SCIENCES
Fostering scholarly communication in the heart of scientific discovery.M S-MEDECINE SCIENCES, published by EDP SCIENCES S A, is an esteemed journal based in France dedicated to the fields of biochemistry, genetics, and medicine. With an ISSN of 0767-0974 and an E-ISSN of 1958-5381, this journal has been a platform for scholarly communication since its inception in 1990 and continues to present critical advancements in these scientific domains, aiming to bridge theoretical research with practical applications. Despite its current Q4 ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories, the journal aspires to enhance its visibility and impact within the academic community. Researchers and professionals can benefit from a wealth of studies that contribute to the understanding of complex biological systems and medical innovations. Interested authors are encouraged to explore the journal's submission guidelines and contribute to the growing body of knowledge in these important fields.